Picture of Gilead Sciences logo

GILD — Gilead Sciences Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareConservativeLarge CapSuper Stock

Momentum

Relative Strength (%)
1m+0.99%
3m+2.19%
6m-4.42%
1yr-6.97%
Volume Change (%)
10d/3m+10.82%
Price vs... (%)
52w High-3.17%
50d MA+2.09%
200d MA+4.28%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)10.48
PEG Ratio (f)n/a
EPS Growth (f)-15.33%
Dividend Yield (f)4.16%
Valuation (ttm)IndustryMarket
Price to Book Value4.19
Price to Tang. Bookn/a
Price to Free Cashflow9.49
Price to Sales3.28
EV to EBITDA8.18

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital20.45%
Return on Equity38%
Operating Margin42.31%

Financial Summary

Year End 31st DecUnit201620172018201920202021E2022ECAGR / Avg
Total Revenue$m30,39026,10722,12722,44924,68926,533.4424,291.96-5.43%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%-12.42-24.93-45.49+0.93-97.74+8205.78-15.33n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for GILD

Why this large-cap dividend could be worth a look background image

Why this large-cap dividend could be worth a look

The compounding effects of reinvesting dividends over the long-term can be spectacular - but finding stocks to help you do it is a challenge... The present economic uncertainty is likely to put sustained pressure on dividend payouts ov...

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202131st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of Gilead Sciences EPS forecast chart

Profile Summary

Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.

Directors

Last Annual
December 31st, 2020
Last Interim
September 30th, 2021
Incorporated
June 22nd, 1987
Public Since
January 1st, 1992
No. of Shareholders
1,402
No. of Employees
13,600
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
1,254,383,522

GILD Share Price Performance

Latest News for GILD

Upcoming Events for GILD

Q4 2021 Gilead Sciences Inc Earnings Release

Q1 2022 Gilead Sciences Inc Earnings Release

Gilead Sciences Inc Annual Shareholders Meeting

Similar to GILD

2Seventy Bio

us flag iconNASDAQ Global Select Market

Picture of 4D Molecular Therapeutics logo

4D Molecular Therapeutics

us flag iconNASDAQ Global Select Market

Picture of AbCellera Biologics logo

AbCellera Biologics

us flag iconNASDAQ Global Select Market

AbSci

us flag iconNASDAQ Global Select Market

Picture of ACADIA Pharmaceuticals logo

ACADIA Pharmaceuticals

us flag iconNASDAQ Global Select Market

FAQ

Or unlock with your email

Or unlock with your email